News and Trends 14 Mar 2023 Astellas menopause study meets endpoints but leukemia drug disappoints …52-week study period. During the double-blind period, treatment-emergent adverse events (TEAEs) occurred in 37% of fezolinetant 30 mg, 43% of 45 mg and 45% of placebo participants. The safety profile… March 14, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jan 2020 Bluebird Bio Launches First Gene Therapy for Beta Thalassemia in Germany …be payable each year depending on whether the therapy prevents the need for transfusions completely. This value-based installment system is also in use for other advanced treatments such as Spark’s… January 14, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Sponsored by KBI Biopharma 17 Sep 2024 ADCs that deliver: The secret lies in rigorous characterization …determined by correlating data from size-exclusion chromatography (SEC) and ultracentrifugation experiments to ensure no degradation or aggregation events are missed due to technological limitations. “As a CDMO, we provide expertise… September 17, 2024 - 7 minutesmins - By Ute Boronowsky Share WhatsApp Twitter Linkedin Email
In Depth 11 Oct 2021 A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology …while fatal toxic events were similar for both therapies. According to the study, the death rate for both therapies was 5.4%. As a comparison, that of immune checkpoint therapy lies… October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022 Astellas meets primary endpoint in gastric cancer study …survival (OS), showing statistical significance for patients treated with zolbetuximab plus mFOLFOX6 compared to placebo plus mFOLFOX6. The most frequent treatment-emergent adverse events (TEAEs) in patients treated with zolbetuximab plus… November 17, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Concern as study says new covid sub-variant is resistant to all therapeutic antibodies …antibodies protect by binding to the viral spike protein, which prevents the virus from entering cells. However, due to mutations in the spike protein, some SARS-CoV-2 variants, particularly the Omicron… November 23, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Sep 2023 Rebuilding relations: U.K. rejoins Horizon Europe to boost funding opportunities …stay in the program. But the events that led to the U.K. rejoining the research program being stalled indefinitely, occurred post-Brexit. Initially, as part of the Brexit deal, it was… September 18, 2023 - 5 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 23 Dec 2022 Watch: The Medicon Valley Alliance celebrates 25th anniversary …and service providers. MVA hosts and co-hosts events, seminars, conferences, and meetings, and helps with networking and knowledge-sharing in the region’s life science community. MVA’s vision is to be the… December 23, 2022 - 1 minutemin - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 21 Dec 2020 Enemy or Valuable Ally? How Biotech Uses Viruses for Good …also have the added benefit of being extremely precise in which bacterial strains they target. This prevents them from killing beneficial bacteria, which is a common problem with conventional antibiotics…. December 21, 2020 - 7 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
Interview 23 Nov 2022 What recent mixed clinical results can teach about Alzheimer’s disease 2022 has provided mixed fortunes for companies aiming to slow Alzheimer’s disease. Ulrich Dauer, CEO of the German biotech Vivoryon, explains the lessons these events provide. The quest for a… November 23, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 20 Jun 2018 “Have the guts to follow your instincts”: Top CEO Talks About His Time in Biotech …perhaps the fundraising ends up being one of the more challenging events. Have you made any mistakes in your career? Is there anything you would change if you were to… June 20, 2018 - 9 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
In Depth 18 Sep 2024 Two targets, one solution: The rise of bispecific antibodies …designed to bind PD-L1 while also engaging CD137. Her explained that by targeting PD-L1, AP203 prevents T cell suppression and enhances immune system detection of cancer cells. Meanwhile, activation of… September 18, 2024 - 9 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email